OBJECTIVE: To present a pooled analysis of the efficacy of rituximab from European cohorts
diagnosed with biopsy-proven lupus nephropathy (LN) who were treated with rituximab. …

Objective. LN is a common and potentially severe complication of SLE. Our aim was to
characterize a LN cohort followed at a single centre for 30 years and assess its evolution over time…

Cardiovascular disease (CVD), comprising coronary heart disease and stroke, is one of the
most important causes of death in patients with systemic lupus erythematosus (SLE). The …

Objective: Patients with systemic lupus erythematosus (SLE) have an increased risk of
developing cardiovascular disease. Standard serum lipid measurements in clinical practice do …

Accelerated atherosclerosis is a complication of the autoimmune rheumatic disease systemic
lupus erythematosus (SLE). We questioned the role played by invariant natural killer T (…

Introduction IgG anti-apolipoprotein A-1 (IgG anti-apoA-1) antibodies are present in patients
with systemic lupus erythematosus (SLE) and may link inflammatory disease activity and the …

SIR, Variability in clinical response to rituximab-induced B cell depletion therapy (BCDT) is
well described in both RA and SLE [1, 2]. Recent evidence suggests that an inadequate …

Systemic lupus erythematosus is a multisystem, autoimmune disease known to be one of the
strongest risk factors for atherosclerosis. Patients with SLE have an excess cardiovascular …

Objective Patients with SLE have increased prevalence of clinical cardiovascular disease (CVD)
and subclinical atherosclerosis. Although 30–40% of patients with SLE have vascular …

Objectives Patients with SLE have an increased risk of developing cardiovascular disease (CVD).
Multiple studies have shown that these patients have increased numbers of carotid …